

Open Access publishing options:
Danish institutions associated
corresponding authors



# **Key information**

# Agreement between Elsevier and the Royal Danish Library National License Consortium (The Current Agreement 2021-2024)

# 1. How do we determine eligibility of the article for the Danish agreement?

- The submission date of the article should be on or after 1st January 2021
- The corresponding author must be from a Danish participating institution
- The article must be from a participating journal (see full list here).

# 2. Why do we use submission date as the eligibility criteria?

- The submission date is the only stable point in the publishing process
   Acceptance and publication dates vary based on the journal processes
- The author controls the submission date. This gives the author not just control, also transparency and predictability however long or short the journal will take for the review and publication process

# Finalize Publishing your Article

Corresponding author receives an email post acceptance with a unique link to complete the author journey and choose publishing options

#### Denmark institutions: Author journey demo

Corresponding author Dr. Lee Chahin

E-mail address leechahin@cphuniv.com

Journal Fuel

Our reference JFUE237969

PII S0016-2361(21)00025-9

#### Welcome Dr. Chahin,

To help us finalize the publication of your article please complete the publishing form(s) below.

Note: you will receive a confirmation e-mail after completing each form.

When placing orders via these forms, you may be asked to provide the information listed below.

Purchase Order Number

If a Purchase Order Number is required for payment by your institution and you already have one, please provide it via the publishing form(s). Note that you may still complete the form(s) now, even if you do not have the Purchase Order number available yet.

• Tax Exemption Number and Tax Exemption Certificate if applicable to your institution.

For Bank and company address details, see the Information you may need to supply to complete the options *¬*.

## Rights and Access


Complete the Rights and Access information form

Elsevier supports responsible sharing. To find out how you can share your article, please visit our Sharing Policy page Z.





- Corresponding author selects his/her affiliation details which we use to identify the authors and match them to the Danish agreement
- In this example author chooses University of Copenhagen



 $\mathsf{Copyright} \, \textcircled{\mathbb{C}}$ 

Cookies are:

University of Copenhagen Faculty of Life sciences

openhagen Faculty of Life sciences

Frederiksberg, DK


Frederiksberg, DK

University of Copenhagen Department of Communication

RELX Group"



# Corresponding author also adds the co-author affiliation details




Previous



Author can add the Funder details if needed. Funder information is needed when author has received research funding

For the Danish agreement, we only use the corresponding author affiliation to present the agreement



Previous

Save and Continue >

- Based on the affiliation details, the author sees the **Publishing Options.** Gold OA option is followed by **Subscription option** and we make it clear that the agreement covers the full publishing fee (APC)
- If the librarian at the consortium rejects the author request in the Elsevier OA Platform, we also make it clear that the authors will receive a full price invoice
- Gold OA is preselected and recommended

Based on information you have provided, your publishing options are shown below

### Gold Open Access

**Publish Open Access** 

Make my published article available to everyone.

As an author affiliated with a Danish institution, upon validation, agreement between the Danish institutions and Elsevier \( \times \) will cover the APC.



Your institution prefers you to publish Gold OA

#### Article Publishing Charge (APC)

If your institution does not approve paying the APC, you will receive an invoice for the APC of EUR 3,320.00 (ex. VAT). You then have the option to either pay the APC invoice or publish your article free of charge under the subscription model. To publish your article under the subscription model, contact Researcher Support within two weeks of the invoice date. Elsevier will send the invoice to the email address you have provided on your author profile.

# Subscription

**Publish Subscription** 

As a corresponding author affiliated with a Danish institution, I will publish my article under the subscription model, making my final published article immediately available to all subscribers.


Elsevier's sharing policy a explains how I can share my accepted manuscript.

#### **ELSEVIER**

# Rights and Access



- In case of Gold OA, author selects the CC License
- CC BY is preselected and recommended




Previous

Save and Continue >



#### **Author selects the rights**





# System presents author with the Journal License Publishing Agreement

#### Denmark institutions: Author journey demo

#### Elsevier Ltd

#### Your Status

. I am one author signing on behalf of all co-authors of the manuscript

#### License of Publishing Rights

I hereby grant to Elsevier Ltd an exclusive publishing and distribution license in the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in print, electronic and all other media (whether now known or later developed), in any form, in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication. This license includes the right to enforce the rights granted hereunder against third parties.

#### Supplemental Materials

"Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

With respect to any Supplemental Materials that I submit, Elsevier Ltd shall have a perpetual worldwide non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Supplemental Materials, in all forms and media (whether now known or later developed) and permit others to do so. The publisher shall apply the same end user license to the Supplemental Materials as to the Article where it publishes the Supplemental Materials with the Article in the journal on its online platforms on an Open Access basis.

#### Research Data

"Research Data" shall mean the result of observations or experimentation that validate research findings and that are published separate to the Article, which can include but are not limited to raw data, processed data, software, algorithms, protocols, and methods.

With respect to any Research Data that I wish to make accessible on a site or through a service of Elsevier Ltd, Elsevier Ltd shall have a perpetual worldwide, non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Research Data in all forms and media (whether now known or later developed), and to permit others to do so. Where I have selected a specific end user license under which the Research Data is to be made available on a site or through a service, the publisher shall apply that end user license to the Research Data on that site or service.

# Authors reads and agrees to the Journal License Publishing Agreement

For further information see the publishing ethics page at https://www.elsevier.com/about/our-business/policies/publishing-ethics  $\square$  and the journal home page. For further information on sanctions, see https://www.elsevier.com/about/our-business/policies/trade-sanctions  $\square$ 

#### Author representations

- The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously
  published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited
  the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses and, if my or any of my coauthors' institution has a policy that might restrict my ability to grant the rights required by this License Agreement (taking into account
  the Scholarly communication rights permitted hereunder), a written waiver of that policy has been obtained.
- If I and/or any of my co-authors reside in Iran, Cuba, Sudan, Burma, Syria, or Crimea, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher's policies relating to the use of such images or personal information. See https://www.elsevier.com/about/our-business/policies/patient-consent > for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms
  of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

#### Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of Elsevier Ltd ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see http://www.elsevier.com/copyright > 1.



I have read and agree to the terms of the License Agreement.


14 January 2021 T-copyright license-v5/2017

Previous

Accept Agreement >



- This is the summary page explaining the choices the author made in the publishing journey
- Corresponding and Coauthors receive a copy of the summary via email
- The article becomes OA on ScienceDirect within 24 hours
- The librarian at the institution will receive a request to validate the eligibility of the author affiliation within 48 hours



14 January 2021

Previous

Finish >



# Thank you

